BIOGRAPHICAL SKETCH

Academic & Professional Background

• B.A. (Chemistry) 1968 - College of Wooster, Wooster, Ohio
• M.D. (Medicine) 1972 - Case Western Reserve University, Cleveland, Ohio

Current Research Interests

• Clinical Trials
• Prostate Cancer
• Renal Cell Carcinoma
• Transitional Cell Carcinoma
• Urologic Cancers

Selected Publications

Jin JK, Walloch J, Flanigan RC , Shankey TV. Intratumor heterogeneity of early (stage A2) prostate adenocarcinomas II. Evaluation of archival tumors by image analysis. Cytometry 27:132-140, 1997.

Dougherty S, Manion S, Walloch J, Flanigan RC , et al. Intratumor heterogeneity of early stage (stage A2) prostate adenocarcinomas: I. Evaluation of archival tumors by flow cytometry. Cytometry 27:126-131, 1997.

Dalkin B, Ahmann F, Flanigan R, et al. Derivation and application of upper limits for prostate specific antigen in men 50 to 74 years of age without clinical evidence of prostate carcinoma. Br J of Urol (accepted for publication), 1997.

Flanigan RC , McKay TC, Olson EC, Shankey TV, Pyle J, Waters WB. Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastases on patients before radical prostatectomy. Urology (accepted for publication), 1997.

Elias L, Blumenstein BA, Kish J, Flanigan RC , Wade JL, Lowe BA, Goodwin JW, Crawford ED. Phase II trial of interferon and 5-fluorouranl in advanced renal cell carcinoma. Cancer (accepted for publication), 1997

Lerner SE, Tsai H, Flanigan RC , Trump DL, Fleischmann J. Renal cell carcinoma: Considerations for nephron sparing surgery. Urology 45:574-577, 1995.

Kotake T, Flanigan RC , Kirkels WJ, Wallace DNA, Prapotnich D, Matsumura Y, Honma Y, Ritchie JP, Newling DWW, Gospadarowicz MK, Hall RR. The current TNM-classification of bladder cancer. Is it as good as we need it to be? Int J of Urol 2:36-40, 1995.

Whitehead RP, Flanigan RC , Wolf MK, Solanki BL, Henstreet GP, Benedetto P, Richman SP, Crawford ED. A phase II trial of continuous infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: A Southwest Oncology Group Study. J Immunotherapy 18:104-114, 1995.

Vasavada S, Manion S, Flanigan RC , Novick A. Renal arteriovenous malformation masquerading as renal cell cancer. Urology 456:716-721, 1995.

Projects Completed or Active (Selected)

• Randomized Trial, Moderate Symptoms, BPH Patients
• Urologic Cancer Outreach Program
• Chemosensitivity in Urologic Cancer
• PSA Screening Hybertech
• Preoperative Predictors of Staging and Prognosis in Prostate Cancer
• Bropirimine/Adult Patients with BCG-Resistant Bladder Carcinoma in situ or with Bladder Carcinoma in situ and Intolerance to BCG

Research Funding Sources

• Hybertech
• Janssen Pharmaceuticals
• Loyola University Medical Center
• National Cancer Institute
• Upjohn
• VA Cooperative Studies
• VA Merit Review

Research Methods Employed

• Southwest Oncology Group - Various Protocols for Urologic Cancers
• Urologic Cancer Outreach Program, NCI

Professional Accomplishments

• 1987-present - Examination Consultant, American Board of Surgery
• 1987-present - Board of Directors, American Cancer Society, Illinois Division
• 1987-present - Medical Advisory Board, National Kidney Foundation of Illinois
• 1988-present - Advisory Council, American College of Surgeons, Metropolitan Chicago Chapter
• 1988-present - Chair, Renal Subcommittee, Southwest Onncology Group
• 1989 - Reviewer: Human Sexuality; Pharmacotherapy; Investigative Urology; Journal of Urology
• 1990-present - Examination Committee, American Board of Urology

Honors

• 1980 - Golden Apple Award, Best Clinical Teacher - University of Kentucky
• 1982-1984 - Junior Faculty Clinical Fellowship - American Cancer Society
• 1996 - Distinguished Alumni, Lima City Schools